Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.7% – What’s Next?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock price was down 6.7% during trading on Friday . The stock traded as low as $13.06 and last traded at $13.03. Approximately 512,066 shares traded hands during trading, a decline of 74% from the average daily volume of 1,984,443 shares. The stock had previously closed at $13.96.

Analyst Ratings Changes

A number of analysts have weighed in on ADPT shares. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Trading Down 11.1%

The stock has a market cap of $1.91 billion, a P/E ratio of -31.02 and a beta of 2.19. The company’s fifty day simple moving average is $15.85 and its 200-day simple moving average is $15.91.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the firm earned ($0.23) EPS. The firm’s revenue for the quarter was up 51.0% compared to the same quarter last year. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 470,266 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the sale, the insider directly owned 1,522,058 shares in the company, valued at approximately $20,045,503.86. This represents a 23.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sharon Benzeno sold 63,103 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $831,066.51. Following the completion of the transaction, the insider directly owned 272,751 shares of the company’s stock, valued at approximately $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,422,544 shares of company stock valued at $35,397,620. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently bought and sold shares of ADPT. XTX Topco Ltd bought a new stake in Adaptive Biotechnologies during the second quarter worth about $793,000. Allianz Asset Management GmbH raised its stake in shares of Adaptive Biotechnologies by 305.8% in the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after acquiring an additional 242,474 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Adaptive Biotechnologies by 82.5% in the 3rd quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock worth $1,019,000 after acquiring an additional 30,785 shares in the last quarter. Affinity Wealth Management LLC acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $4,541,000. Finally, Huntleigh Advisors Inc. bought a new stake in Adaptive Biotechnologies during the 3rd quarter worth approximately $1,227,000. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.